生物技术公司Elicio Therapeutics宣布,其疗法在微卫星稳定/错配修复功能缺陷(MSS/MMR-p)患者群体中观察到了完全缓解。这一患者群体历史上曾对检查点抑制剂产生过治疗反应,此次数据为针对该难治性癌症类型的免疫疗法带来了新的希望。
生物技术公司Elicio Therapeutics宣布,其疗法在微卫星稳定/错配修复功能缺陷(MSS/MMR-p)患者群体中观察到了完全缓解。这一患者群体历史上曾对检查点抑制剂产生过治疗反应,此次数据为针对该难治性癌症类型的免疫疗法带来了新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.